# Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

> **NCT06644495** · — · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 1000 (estimated)

## Conditions studied

- NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06644495
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644495, "Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06644495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*